Cirillo Nicola, Morgan David J, Pedicillo Maria Carmela, Celentano Antonio, Lo Muzio Lorenzo, McCullough Michael J, Prime Stephen S
Melbourne Dental School, The University of Melbourne, 720 Swanston Street, Carlton, Melbourne, VIC 3053, Australia.
School of Cellular &Molecular Medicine, University of Bristol, Bristol BS8 1TD, UK.
Br J Cancer. 2017 Sep 26;117(7):984-993. doi: 10.1038/bjc.2017.243. Epub 2017 Aug 10.
Recent studies have shown that production of cortisol not only takes place in several non-adrenal peripheral tissues such as epithelial cells but, also, the local inter-conversion between cortisone and cortisol is regulated by the 11β-hydroxysteroid dehydrogenases (11β-HSDs). However, little is known about the activity of this non-adrenal glucocorticoid system in cancers.
The presence of a functioning glucocorticoid system was assessed in human skin squamous cell carcinoma (SCC) and melanoma and further, in 16 epithelial cell lines from 8 different tissue types using ELISA, western blotting and immunofluorescence. 11β-HSD2 was inhibited both pharmacologically and by siRNA technology. Naïve CD8 T cells were used to test the paracrine effects of cancer-derived cortisol on the immune system in vitro. Functional assays included cell-cell adhesion and cohesion in two- and three-dimensional models. Immunohistochemical data of 11β-HSD expression were generated using tissue microarrays of 40 cases of human SCCs as well as a database featuring 315 cancer cases from 15 different tissues.
We show that cortisol production is a common feature of malignant cells and has paracrine functions. Cortisol production correlated with the magnitude of glucocorticoid receptor (GR)-dependent inhibition of tumour-specific CD8 T cells in vitro. 11β-HSDs were detectable in human skin SCCs and melanoma. Analyses of publicly available protein expression data of 11β-HSDs demonstrated that 11β-HSD1 and -HSD2 were dysregulated in the majority (73%) of malignancies. Pharmacological manipulation of 11β-HSD2 activity by 18β-glycyrrhetinic acid (GA) and silencing by specific siRNAs modulated the bioavailability of cortisol. Cortisol also acted in an autocrine manner and promoted cell invasion in vitro and cell-cell adhesion and cohesion in two- and three-dimensional models. Immunohistochemical analyses using tissue microarrays showed that expression of 11β-HSD2 was significantly reduced in human SCCs of the skin.
The results demonstrate evidence of a cancer-associated glucocorticoid system and show for the first time, the functional significance of cancer-derived cortisol in tumour progression.
最近的研究表明,皮质醇不仅在一些非肾上腺外周组织(如上皮细胞)中产生,而且可的松和皮质醇之间的局部相互转化受11β-羟基类固醇脱氢酶(11β-HSDs)调节。然而,关于这种非肾上腺糖皮质激素系统在癌症中的活性知之甚少。
使用酶联免疫吸附测定(ELISA)、蛋白质免疫印迹法和免疫荧光法,评估人皮肤鳞状细胞癌(SCC)和黑色素瘤以及来自8种不同组织类型的16种上皮细胞系中功能性糖皮质激素系统的存在情况。通过药理学方法和小干扰RNA(siRNA)技术抑制11β-HSD2。使用未经刺激的CD8 T细胞在体外测试癌症衍生的皮质醇对免疫系统的旁分泌作用。功能测定包括二维和三维模型中的细胞间粘附和凝聚。使用40例人皮肤SCC的组织芯片以及一个包含来自15种不同组织的315例癌症病例的数据库生成11β-HSD表达的免疫组织化学数据。
我们发现皮质醇的产生是恶性细胞的一个共同特征,并具有旁分泌功能。皮质醇的产生与体外糖皮质激素受体(GR)依赖性对肿瘤特异性CD8 T细胞抑制的程度相关。在人皮肤SCC和黑色素瘤中可检测到11β-HSDs。对11β-HSDs公开可用的蛋白质表达数据的分析表明,在大多数(73%)恶性肿瘤中11β-HSD1和-HSD2表达失调。通过18β-甘草次酸(GA)对11β-HSD2活性进行药理学操作以及通过特异性siRNAs使其沉默可调节皮质醇的生物利用度。皮质醇还以自分泌方式发挥作用,在体外促进细胞侵袭,并在二维和三维模型中促进细胞间粘附和凝聚。使用组织芯片的免疫组织化学分析表明,人皮肤SCC中11β-HSD2的表达显著降低。
结果证明了存在与癌症相关的糖皮质激素系统,并首次显示了癌症衍生的皮质醇在肿瘤进展中的功能意义。